Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 4, 282-291, April 2005; doi:10.1634/theoncologist.10-4-282
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubey, S.
Right arrow Articles by Schiller, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dubey, S.
Right arrow Articles by Schiller, J. H.

Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab

Sarita Dubey, Joan H. Schiller

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA

Correspondence: Joan H. Schiller, M.D., K4/548, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Telephone: 608-263-5389; Fax: 608-265-8131; e-mail: jhschill{at}facstaff.wisc.edu

Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade®; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux®; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.

Key Words. Lung cancer • Pemetrexed • Bortezomib • Cetuximab




This article has been cited by other articles:


Home page
 JCOHome page
E. N. Vinageras, A. de la Torre, M. O. Rodriguez, M. C. Ferrer, I. Bravo, M. M. del Pino, D. A. Abreu, S. A. Brooks, R. Rives, C. del Castillo Carrillo, et al.
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 20, 2008; 26(9): 1452 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
I. Velikyan, A. L. Sundberg, O. Lindhe, A. U. Hoglund, O. Eriksson, E. Werner, J. Carlsson, M. Bergstrom, B. Langstrom, and V. Tolmachev
Preparation and Evaluation of 68Ga-DOTA-hEGF for Visualization of EGFR Expression in Malignant Tumors
J. Nucl. Med., November 1, 2005; 46(11): 1881 - 1888.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement